Osteoporosis F3: Low bone density, diabetes with lower back pain, chronic kidney problem, maleinfertility, prostate enlargement or heart problem.

1. Low bone density: 50 patients age from 61 to 84 years old, 19 male and 31 female, took F3 from six months to five years and all were improved in joint pains, bone density, numbness and other related symptoms. There is a positive relationship between the time of administration and the symptom improvement rate.

2. Diabetes: Several studies show F3 or its modification is effective in controlling glucose level in diabetes patients. Of 54 diabetes patients randomly divided into the treatment group taking F3 and the comparison group taking regular anti-diabetes drugs for a year. The total effective rates were 77.8 percent in the treatment group while only 48.1 percent in the comparison group. Other reports on hundreds of patients who took F3 showed the average improvement rates of the following diabetes-related symptoms are: 1. Numbness: 70.78 percent; 2. Blurred vision: 52.27 percent; 3. Leg pain: 68.4 percent; 4. Cold sensation: 66.67 percent; 5. Lower back pain and weak knee: 70 percent; 6. Frequent urination: 50 percent; 7. Itchy skin: 30.8 percent; and 8. Thirsty: 58.3 percent.

3. Chronic heart failure: 127 patients age from 35 to 82 years old with heart failure histories from one to 10 years were divided into the comparison group using Digoxin, Hydrochlorothiazide, Nifedipine, Dobutamine hydrochlouide and other drugs. The treatment group using F3 along with the drugs mentioned above. The results is: significant improved: 53 percent vs. 36 percent. And the total improvement rate is 88 percent vs. 77 percent.

4. Chronic kidney disease, nephritis: 41 chronic nephritis patients took F3 and 4 significantly improved (9.75 percent), 34 improved (82.92 percent) and three did not (7.31 percent).

5. Infertility: F3 is effective for the low-sperm count and low sperm activity male (29 to 69 percent improvement).

6. Prostate enlargement: 25 patients took F3 and 21 patients improved (53.03 percent). Of 192 prostate-enlargement patients, age from 50 to 72 years old, took F3 from 4 to 16 weeks found 116 were cured (60.41 percent), 68 improved (35.41 percent) and 8 did not improve (4.16 percent).

Toxicity and side effects: Few patients (less than 7 percent) may experience minor constipation or stomach discomfort after taking F3.